1. Introduction {#s0005}
===============

Coronaviruses belong to the *Coronavirinae* subfamily, family *Coronaviridae* and order *Nidovirales*. The subfamily members based on genomic structure and phylogenetic study can be classified under four genera --- *Alpha-, Beta-, Gamma- and Delta-coronavirus* ([@b0030]). The first two genera cause infections in only mammals while birds and mammals are commonly infected by *Gamma- and Delta-coronaviruses* ([@b0180]). While *Alpha-coronaviruses* and *Beta-coronaviruses* are known to cause gastroenteritis in animals, in humans, they commonly cause respiratory distress ([@b0030]). There are four human coronaviruses such as HCoV-229E, HKU1, HCoV-NL63 and HCoV-OC43 which induce mild upper respiratory infections and two highly pathogenic ones, such as Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus (MERS-CoV) implicated in severe respiratory syndrome in humans ([@b0050], [@b0155]). All human coronaviruses are reported to have animal origins based on the current sequence studies, for example, SARS-CoV, MERS-CoV, HCoV-229E and HCoV-NL63 have been originated in bats while HKU1 and HCoV-OC43 are probably linked to rodents ([@b0050], [@b0155]). The intermediate hosts such as domestic animals may play a significant role in facilitating the easy transfer of viruses from natural hosts to humans ([@b0030]). Furthermore, domestic animals themselves are susceptible to bat-borne or closely related coronavirus diseases ([@b0085], [@b0150]). At present, 7 of 11 species of *Alpha-coronavirus* specified by the International Committee on Taxonomy of Viruses (ICTV) and 4 of 9 species of *Beta-coronavirus* have been reported only in bats. Consequently, bats are probably the main natural reservoirs of *Alpha- and Beta-coronaviruses* ([@b0180]).

Coronaviruses are enveloped viruses of about 80--120 nm in diameter, with round and often pleiomorphic virions. They contain positive-strand RNA, with the largest genome (\~30 kb) known till date ([@b0090]). A helical capsid found within the viral membrane is composed of genomic RNA complexed with the basic nucleocapsid (N) protein. All coronaviruses display at least three membrane viral proteins. This includes type I glycoprotein, spike (S) protein which forms peplomers on the surface and gives a characteristic crown-like appearance, the membrane (M) protein and a small membrane protein, an envelope protein (E). All coronaviruses have a similar genomic structure ([@b0170]). The replicase gene located within 5′ region approximately 20--22 kb encodes several enzymatic activities. The gene products of the replicase are encoded within two very large open reading frames, ORFs 1a and 1b, which are translated by a frameshift mechanism into two large polypeptides, pp1a and pp1ab ([@b0055], [@b0100]). With the help of S protein, coronaviruses bind to their specific host cellular receptors. On gaining entry into the cell, pp1a and pp1ab are translated from the viral genome RNA, ORFs 1a and 1b ([@b0020], [@b0025]). The ORF1a encodes a picornavirus 3C-like protease (3CL^pro^) and one or two papain-like proteases (PL^pro^ or PLP). These proteases catalyze the processing of viral pp1a and pp1ab into the mature replicase proteins ([@b0100], [@b0200]). The enzymes such as RNA-dependent RNA polymerase (RdRp), a helicase (1 1 6) and others are encoded in ORF 1b and processed from pp1ab ([@b0055]). The metabolism of coronavirus RNA and disruption of host cell processes are believed as a result of the catalytic activities of various enzymes ([@b0195]).

As aforementioned, SARS- and MERS-CoVs genome harbours two ORFs: ORF1a and ORF1b wherein ORF1a encodes two cysteine proteases viz; a papain-like protease (PL^pro^) and a 3C-like protease (3CL^pro^) also known as main protease (M^pro^). While PL^pro^ manages cleavage on the first three cutting sites of its polyprotein, 3CL^pro^ is responsible for cleavage at other eleven positions causing the release of sixteen non-structural proteins (nsp) ([@b0075]). The crystal structures of SARS- and MERS-CoVs 3CL^pro^ reveal the presence of three structural domains in each monomer wherein domains I and II has a characteristic chymotrypsin-like fold with a catalytic cysteine and are linked to a third C-terminal domain by a long loop ([@b0125]). Therefore, 3CL^pro^ is an important drug target against coronaviral infection as the auto-cleavage process is indispensable for viral maturation and replication ([@b0075]).

The recent outbreak of new coronavirus pandemic or coronavirus disease 2019 (COVID-19) has caused high mortality rate and infections around the world ([@b0185], [@b0190]) warrants the need for the discovery of new effective antiviral therapeutics against coronaviral infections. There are no approved antiviral drugs or vaccines for the treatment of human CoV infection to date, though many candidate therapeutics have been investigated in pre-clinical studies ([@b0005], [@b0035], [@b0060], [@b0110], [@b0135]). Although many attempts have been previously made by workers to identify specific inhibitors for 3CL^pro^ enzymes, a few studies have been done to target all the three coronavirus protease enzymes (SARS-CoV-2 3CL^pro^, SARS-CoV 3CL^pro^ and MERS-CoV 3CL^pro^) using small molecules. In this study we aimed at finding suitable lead molecules for the inhibition of 3CL^pro^ enzymes through virtual screening of two chemical datasets viz; Food and Drug Administration (FDA) approved antiviral drugs and selected phytochemicals. We have proposed five lead molecules as potential inhibitors for each enzyme targets. These lead molecules could be further investigated for developing as drugs against anti-coronaviral infection.

2. Materials and methods {#s0010}
========================

2.1. Selection and retrieval of phytochemicals and FDA approved drugs {#s0015}
---------------------------------------------------------------------

A total of 263 phytochemicals and 75 FDA approved antiviral drugs were retrieved from the database of Indian Plants, Phytochemistry And Therapeutics (IMPPAT) ([@b0115]) and DrugBank database ([@b0175]) respectively. The three-dimensional structure of the molecules was downloaded in SDF format and the molecules whose only two-dimensional structures were available, were converted into the three-dimensional form using OpenBabel software version 2.4.1 ([@b0130]) and optimized using the Merck molecular force field (MMFF94) ([@b0065]).

2.2. Screening of drug-like compounds: {#s0020}
--------------------------------------

The drug-like compounds from the phytochemicals set were filtered based on Lipinski's rule of five ([@b0105]), Veber's rule ([@b0165]) and Adsorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) physicochemical parameters. The physicochemical properties of the compounds were evaluated using DataWarrior program version 5.0 ([@b0145]).

2.3. Protein-preparation {#s0025}
------------------------

The high resolution three dimensional X-ray crystal structures of the enzyme target: SARS-CoV-2 3CL^pro^, SARS-CoV 3CL^pro^ and MERS-CoV 3CL^pro^ were retrieved from protein data bank (PDB) (<http://www.rcsb.org/>) using their accession IDs 6Y2F, 3TNT and 5WKK at a resolution of 1.95 Å, 1.59 Å and 1.55 Å respectively. The heteroatoms including ions, cocrystal ligands (O6K, G85 and AW4 corresponding to PDB IDs: 6Y2F, 3TNT and 5WKK respectively) and water molecules were removed. Hydrogen atoms and Kolmann charges were added to the protein using AutoDockTools 1.5.6 ([@b0120]) and the proteins were converted into PDBQT format.

2.4. Ligand preparation {#s0030}
-----------------------

The selected compounds were prepared for docking using AutoDockTools 1.5.6 ([@b0120]). Hydrogen atoms and Gasteiger charges were added to the selected compounds and the torsions were defined for each compound. The structures were saved in PDBQT format.

2.5. Molecular docking study {#s0035}
----------------------------

The binding affinity of each selected compound along with the control with the three enzyme targets was determined using molecular docking approach. The binding sites for the docking were defined by placing a grid box of suitable dimensions centred at each cocrystallized ligand ([Table 1](#t0005){ref-type="table"} ). Autodock Vina was used for carrying out molecular docking, which performs docking calculations based on sophisticated gradient optimization method ([@b0160]). The binding poses were clustered and ranked in the order of their binding affinities. The molecular interactions (hydrogen bonds and hydrophobic interactions between the target proteins and compounds were studied using LigPlot + version 1.4.5 ([@b0095]).Table 1The grid box parameters considered for molecular docking studies.Enzyme targetsAutoDock Vina Search SpaceCenterDimensions (Å)ExhaustivenessSARS-CoV-2 3CL^pro^x: 10.9372, y: −2.0146, z: 18.269225 × 25 × 258SARS-CoV 3CL^pro^x: 25.1486, y: 44.1145, z: −5.612125 × 25 × 258MERS-CoV 3CL^pro^x: −21.9860, y: 25.6036, z: 4.004525 × 25 × 258

3. Results and discussion {#s0040}
=========================

3.1. Virtual screening of drug-like compounds: {#s0045}
----------------------------------------------

A set of 75 FDA approved antiviral drugs and 263 phytochemicals belonging to different classes such as prenol lipids, flavonoids, indoles and derivatives, alkaloids, lignans, organooxygen compounds etc. were used for the present study. Since the FDA approved drugs have already undergone the preclinical and clinical trials and tested safe in patients, the drugs were not tested again using *in silico* drug-like filters. While plant-derived compounds are much safer to use with fewer adverse effects, we subjected them into virtual screening protocol to reduce the drug-attrition rate. We used the rule of five (ROF) and Veber's rule filters to test the oral bioavailability of the compounds. According to ROF, a compound is considered to be orally bioactive if their physicochemical properties lie within the safe limits (molecular weight ≤ 500 Da, hydrogen bond donors ≤ 5, hydrogen bond acceptors ≤ 10, and an octanol--water partition coefficient log P ≤ 5) ([@b0105]). Veber\'s rule states that a good oral bioavailable compound possesses number of rotatable bonds ≤ 10 and topological polar surface area ≤ 140 Å^2^ ([@b0165]). Further, the molecules were also tested for *in silico* toxicity studies. Out of 263 phytochemicals, 46 molecules were found to be orally bioactive, non-tumorigenic, non-mutagenic, non-irritant and without any side effects on reproductive health. Thus, these 46 phytochemicals and 75 FDA approved drugs were tested further for their inhibitory potential against the three enzyme targets ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"} ).Table 2List of FDA approved antiviral drugs selected for molecular docking studies.DrugsDrugBank IDTherapyOmbitasvirDB09296Chronic Hepatitis CElbasvirDB11574Chronic Hepatitis C[Sofosbuvir]{.ul}DB08934Chronic Hepatitis CLedipasvirDB09027Chronic Hepatitis CFamciclovirDB00426Herpes virus infectionsSimeprevirDB06290Chronic hepatitis C virusLopinavirDB01601Human immunodeficiency virus type 1 (HIV-1) infection.TecovirimatDB12020SmallpoxOseltamivirDB00198Influenza viruses A and B infectionsBaloxavir marboxilDB13997Influenza A and influenza B infectionsDidanosineDB00900HIV infectionBictegravirDB11799HIV-1 and HIV-2 infectionAdefovir dipivoxilDB00718Hepatitis BZalcitabineDB00943HIV infectionEmtricitabineDB00879HIV-1 infectionZidovudineDB00495HIV infectionDarunavirDB01264HIV-1 infectionNevirapineDB00238HIV-1 infection and AIDS.ValganciclovirDB01610Cytomegalovirus infectionsNelfinavirDB00220HIV infectionFoscarnetDB00529cytomegalovirus retinitis, HIV infectionBoceprevirDB08873Chronic Hepatitis CInosine pranobexDB13156Viral infectionDolutegravirDB08930HIV-1 infectionAbacavirDB01048HIV infection and AIDS.EdoxudineDB13421Herpes simplex virus type 1 and 2 infectionRibavirinDB00811Hepatitis C and viral hemorrhagic feversElvitegravirDB09101HIV-1 infectionAmantadineDB00915Influenza A infectionVidarabineDB00194Herpes viruses, the vaccinia virus and varicella zoster virus infectionDaclatasvirDB09102Hepatitis C Virus (HCV) infectionTenofovir alafenamideDB09299Chronic hepatitis B and HIV-1 infectionRitonavirDB00503HIV infectionTrifluridineDB00432Keratoconjunctivitis and recurrent epithelial keratitisZanamivirDB00558Influenza A and B virus infectionAcyclovirDB00787Herpes simplex, *Varicella zoster*, herpes zoster infectionGanciclovirDB01004AIDS-associated cytomegalovirus infections.EntecavirDB00442Hepatitis B infectionRaltegravirDB06817HIV infectionDoravirineDB12301HIV-1 InfectionPibrentasvirDB13878Hepatitis C virus (HCV) infectionFosamprenavirDB01319HIV infectionGlecaprevirDB13879HCV infectionTipranavirDB00932HIV infectionEtravirineDB06414HIV-1 infectionAmprenavirDB00701HIV infection.LetermovirDB12070Cytomegalovirus (CMV) infectionFavipiravirDB12466InfluenzaIdoxuridineDB00249Herpes simplex virus (HSV) infectionRimantadineDB00478Influenza.TromantadineDB13288Herpes zoster and simplex virus infectionTelaprevirDB05521Chronic Hepatitis CDasabuvirDB09183Chronic Hepatitis CGrazoprevirDB11575Chronic Hepatitis CDocosanolDB00632HSV infectionPenciclovirDB00299HSV infectionsVelpatasvirDB11613chronic Hepatitis CTenofovir disoproxilDB00300HIV infection and Hepatitis BCidofovirDB00369CMV retinitisVoxilaprevirDB12026Chronic Hepatitis CAsunaprevirDB11586HCV infectionValaciclovirDB00577Hepatitis, HIV, and cytomegalovirus infectionEfavirenzDB00625HIV-1 infectionPeramivirDB06614Influenza A/B.BrivudineDB03312Herpes zoster.TelbivudineDB01265Hepatitis B virus infectionMaravirocDB04835HIV infectionStavudineDB00649HIV infectionParitaprevirDB09297Chronic Hepatitis CIndinavirDB00224HIV infectionLamivudineDB00709HIV-1 and hepatitis B virus (HBV) infectionAtazanavirDB01072HIV infectionRilpivirineDB08864HIV-1 infectionDelavirdineDB00705HIV-1.infectionSaquinavirDB01232HIV-1 and HIV-2 infectionTable 3List of phytochemicals selected for the docking studies (MW: molecular weight; cLogP: octanol--water partition coefficient; cLogS: aqueous solubility at 25° and pH = 7.5; HBA: hydrogen bond acceptor; HBD: hydrogen bond donor; TPSA (Å^2^): Topological polar surface area; RB: rotatable bonds).Molecule NameCASID/CHEMSPIDER/CIDClassMWcLogPcLogSHBAHBDTPSARBDruglikenessHeterophylloidine78174--97-7Prenol lipids383.4862.2205−3.415063.6822.7882Arjunolone82178--34-5Flavonoids284.2662.6114−3.175275.9920.40331Rosicine95690--65-6Indoles and derivatives324.3790.8137−3.0915154.122.2389Asparagamine A156798--15-1Organooxygen compounds385.4582.1085−3.6346057.2330.7051Piscrocin B752225--57-3Heteroaromatic compounds198.173−0.1119−1.2625390.920.205696-Acetylheteratisine10,246,449Quinolidines433.5431.1579−3.1867185.344.6497Gummadiol10,308,017Furanoid lignans386.3552.0507−3.7528295.8420.1606Vidolicine28,288,759Indoles and derivatives352.4331.5661−3.475154.132.575419-Hydroxy-11-methoxytabersonine57,619,488Plumeran-type alkaloids382.4581.3822−3.2466271.0340.90699Boldine10,154Aporphines327.3792.7882−3.1295262.1624.6712Indoline10,328Indoles and derivatives119.1661.3351−2.0251112.0300.19917Tubotaiwine100,004Strychnos alkaloids324.4232.3452−3.5684141.5731.5804Cinchonidine101,744Cinchona alkaloids294.3972.6804−3.0793136.3630.88095Tryptoline107,838Indoles and derivatives172.231.2188−2.392227.8201.1795Alloyohimbine120,716Yohimbine alkaloids354.4482.3512−3.0655265.5621.5035Cuscohygrine1,201,543Alkaloids and derivatives224.3471.2932−1.223023.5544.2839Sebiferine10,405,046Phenanthrenes and derivatives341.4061.9462−2.753504835.7459Condylocarpine10,914,255Strychnos alkaloids322.4072.2523−3.3044141.5720.2911419,20-Dihydroakuammicine11,023,792Alkaloids and derivatives324.4232.3452−3.5684141.5732.1615Lochnericine11,382,599Aspidospermatan-type alkaloids352.4331.5996−3.5385154.132.38853-Isoajmalicine11,416,867Yohimbine alkaloids352.4332.2674−3.1415154.5622.6043Vindolidin11,618,751Plumeran-type alkaloids426.5111.3936−3.0987179.3153.2845Vincapusine11,646,359Alkaloids and derivatives368.4322.6409−2.6956163.9332.2856Epibubbialine11,830,997Azaspirodecane derivatives221.255−0.1874−1.4244149.7701.6204Vindoline11,953,805Plumeran-type alkaloids456.5371.3236−3.1168188.5463.28451,2-Dihydrovomilenine11,953,964Ajmaline-sarpagine alkaloids352.4331.8244−3.6545261.821.1872Pericyclivine11,969,544Macroline alkaloids322.4072.8635−3.0384145.3320.20237Lycoctonine11,972,492Prenol lipids467.601−0.1645−1.82483100.8560.56009Cathanneine12,302,545Aspidospermatan-type alkaloids426.5111.3713−3.4087068.3152.5051Anahygrine12,306,778Alkaloids and derivatives224.3471.3823−1.8523132.3443.0573Tabernaemontanin12,309,360Vobasan alkaloids354.4482.6197−3.6785162.433.15334-Methoxynorsecurinine101,091,319Pyrrolizidines233.266−0.0349−1.3244038.7711.5563Akuammicine101,281,350Strychnos alkaloids322.4072.2523−3.3044141.5720.87991Heterophyllisine101,289,617Quinolidines375.5071.5254−3.175515924.4531Germacranolide101,616,641Prenol lipids266.3362.1659−2.3714266.7601.5629Isoajmaline101,624,670Ajmaline-sarpagine alkaloids326.4381.791−3.4844246.9413.4513Hetidine101,685,340Prenol lipids357.4480.8838−2.6015277.8402.8009Catharosine101,686,461Plumeran-type alkaloids384.4740.909−2.6886273.2433.3742Fluorocarpamine101,688,177Carboxylic acids and derivatives339.4141.8706−3.0955158.6420.97774Ajmalicidine101,927,009Indoles and derivatives370.4473.0403−3.4386163.9322.2403Hetisinone101,930,090Prenol lipids327.4231.0959−2.9034260.7700.86256Rhazimol101,986,486Corynanthean-type alkaloids338.4060.2205−2.555273.1322.610418-Hydroxy-3-epi-alpha-yohimbine102,004,710Yohimbine alkaloids370.4471.4991−2.6666385.7922.3334Sarpagine102,090,391Macroline alkaloids310.3962.4395−2.6324359.4912.0345Velbanamine102,399,433Indoles and derivatives298.4283.3453−3.2063239.2613.5116Catharosine2564--23-0Plumeran-type alkaloids384.4740.909−2.6886273.2433.3742

3.2. Top ranked lead molecules for SARS-CoV-2 3CL^pro^ from a set of phytochemicals and FDA approved drugs: {#s0050}
-----------------------------------------------------------------------------------------------------------

The top five leads-102004710 (18-Hydroxy-3-epi-alpha-yohimbine), 120,716 (Alloyohimbine), 10,308,017 (Gummadiol), 156798--15-1 (Asparagamine A) and 11,646,359 (Vincapusine) for SARS-CoV-2 3CL^pro^ obtained using molecular docking studies of phytochemicals showed binding energies of −8.1 kcal/mol, −8.0 kcal/mol, −7.8 kcal/mol, −7.6 kcal/mol and −7.5 kcal/mol respectively. Molecular docking of FDA approved antiviral drugs yielded top 5 lead molecules-DB06290 (Simeprevir), DB09027 (Ledipasvir), DB09297 (Paritaprevir), DB13879 (Glecaprevir) and DB09102 (Daclatasvir) which showed binding energies of −9.7 kcal/mol, −9.3 kcal/mol, −9.3 kcal/mol, −9.3 kcal/mol and −9.2 kcal/mol respectively. The control α-ketoamide 13a inhibitor (O6K) displayed binding energy of −7.2 kcal/mol. All the lead compounds showed stable interactions with the target through a good number of hydrogen bonds as well as hydrophobic interactions except for 156798--15-1 (Asparagamine A) which exhibited only hydrophobic interactions. Interestingly, compared to the phytochemicals the FDA-approved antiviral drugs showed higher binding affinities to the target. Further, the lead molecules-10308017 (Gummadiol), 11,646,359 (Vincapusine) and DB13879 (Glecaprevir) showed the potential antiviral activity through hydrogen bond interactions with either His41 or Cys145, both of the residues constitute the catalytic dyad of SARS-CoV-2 3CL^pro^ enzyme.

3.3. Top ranked lead molecules for SARS-CoV 3CL^pro^ from a set of phytochemicals and FDA approved drugs: {#s0055}
---------------------------------------------------------------------------------------------------------

Among the phytochemicals, top 5 leads-120716 (Alloyohimbine), 10,308,017 (Gummadiol), 11,646,359 (Vincapusine), 82178-34-5 (Arjunolone), 102,004,710 (18-Hydroxy-3-epi-alpha-yohimbine) showed binding energies of −9.0 kcal/mol, −8.4 kcal/mol, −8.3 kcal/mol, −8.1 kcal/mol and −8.0 kcal/mol respectively. Using molecular docking of FDA approved antiviral drugs, top 5 leads-DB13879 (Glecaprevir), DB13878 (Pibrentasvir), DB01072 (Atazanavir), DB09102 (Daclatasvir) and DB11574 (Elbasvir) were shortlisted which displayed binding energies of −9.7 kcal/mol, −9.3 kcal/mol, −9.2 kcal/mol, −9.2 kcal/mol and −8.8 kcal/mol respectively. The molecular binding between these lead compounds and the target is strengthened by a good number of hydrogen bonds and hydrophobic interactions. The leads which displayed hydrogen bond interactions with the catalytic residues-His41 and Cys145 include DB13879 (Glecaprevir), DB11574 (Elbasvir), 10,308,017 (Gummadiol) and 102,004,710 (18-Hydroxy-3-epi-alpha-yohimbine). The control, SG85 inhibitor (G85) showed binding energy of −8.0 kcal/mol with the enzyme target.

3.4. Top ranked lead molecules for MERS-CoV 3CL^pro^ from a set of phytochemicals and FDA approved drugs: {#s0060}
---------------------------------------------------------------------------------------------------------

Few lead compounds were also identified for MERS-CoV 3CL^pro^ using molecular docking of phytochemicals and the binding energies of top 5 leads-11646359 (Vincapusine), 120,716 (Alloyohimbine), 10,308,017 (Gummadiol), 11,969,544 (Pericyclivine) and 28,288,759 (Vidolicine) were −9.8 kcal/mol, −8.6 kcal/mol, −8.4 kcal/mol, −8.4 kcal/mol and −8.3 kcal/mol respectively. Among, the FDA approved antiviral drugs, the top 5 leads-DB01072 (Atazanavir), DB06817 (Raltegravir), DB09296 (Ombitasvir), DB08864 (Rilpivirine) and DB09297 (Paritaprevir) scored binding energies of −9.1 kcal/mol, −9.1 kcal/mol, −9.0 kcal.mol, −8.7 kcal/mol and −8.7 kcal/mol respectively. The control, GC813 inhibitor (AW4) showed binding energy of −8.0 kcal/mol. All the lead compounds established both a good number of hydrogen bonds as well as hydrophobic interactions with the target except 28,288,759 which exhibited only hydrophobic interactions. The lead molecules-DB06817 (Raltegravir), 120,716 (Alloyohimbine) and 11,969,544 (Pericyclivine) established hydrogen bond interactions with either His41 or Cys148 or both (catalytic dyad) which may explain their mode of inhibition against the enzyme target.

3.5. Common lead molecules as potential dual or triple inhibitors of the enzyme targets {#s0065}
---------------------------------------------------------------------------------------

Among the FDA approved antiviral drugs, we found that DB13879 (Glecaprevir) and DB09102 (Daclatasvir) can be potential leads for dual inhibition of SARS-CoV-2 3CL^pro^ ([Fig. 1](#f0005){ref-type="fig"} A, B) and SARS-CoV 3CL^pro^ as they were common top 5 leads. The lead molecule DB09297 (Paritaprevir) can be explored as a dual inhibitor of SARS-CoV-2 3CL^pro^ ([Fig. 1](#f0005){ref-type="fig"}C) and MERS-CoV 3CL^pro^ and DB01072 (Atazanavir) can be used as an inhibitor for dual inhibition of SARS-CoV 3CL^pro^ and MERS-CoV 3CL^pro^. While Glecaprevir, Daclatasvir and Paritaprevir have been used against chronic hepatitis C ([@b0045], [@b0070]), Atazanavir (HIV-1 protease inhibitor) is primarily used for the treatment of HIV infection ([@b0040]). Interestingly, we found that the phytochemicals 11,646,359 (Vincapusine), 120,716 (Alloyohimbine) and 10,308,017 (Gummadiol) were common top 5 leads among the three targets and therefore, these phytochemicals can be used as triple inhibitors of SARS-CoV-2 3CL^pro^ ([Fig. 2](#f0010){ref-type="fig"} A--C), SARS-CoV 3CL^pro^ and MERS-CoV 3CL^pro^. The phytochemical 102,004,710 (18-Hydroxy-3-epi-alpha-yohimbine) was identified to be a potential dual inhibitor of SARS-CoV-2 3CL^pro^ and SARS-CoV 3CL^pro^. Vinacapusine is a β-amino alcohol-type alkaloid extracted from leaves of *Catharanthus pusillus*, a traditional medicinal plant of India believed to possess oncolytic properties ([@b0080]). Gummadiol belongs to the class of Furanoid lignans which can be extracted from *Gmelina arborea* ([@b0015], [@b0140]). Alloyohimbine and 18-Hydroxy-3-epi-alpha-yohimbine are alkaloids which are isomeric forms of yohimbine, an alkaloid extracted from the bark of the tree *Pausinystalia yohimbe* and has been traditionally used for the treatment of sexual disorders ([@b0010]). However, the bioactivity of these compounds against viral infections have not been reported till date to the best of our knowledge and therefore these are novel phytochemical leads which could be further explored against coronavirus infections in humans. The key findings from the present study has been illustrated with [Fig. 3](#f0015){ref-type="fig"} .Fig. 1The binding poses and LigPlot + results showing molecular interaction between SARS-CoV-2 3CL^pro^ and lead molecules-(FDA approved antiviral drugs) (A) DB13879 (Glecaprevir) (B) DB09102 (Daclatasvir) (C) DB09297 (Paritaprevir). The hydrophobic interacting residues are indicated by red arcs with spikes and the green dashed lines with the bond distance correspond to hydrogen bonds.Fig. 2The binding poses and LigPlot + results showing molecular interaction between SARS-CoV-2 3CLpro and lead molecules-(Phytochemicals) (A) 11,646,359 (Vincapusine) (B) 120,716 (Alloyohimbine) (C) 10,308,017 (Gummadiol). The hydrophobic interacting residues are indicated by red arcs with spikes and the green dashed lines with the bond distance correspond to hydrogen bonds.Fig. 3A graphical summary illustrating the key findings from the present study.

4. Conclusion {#s0070}
=============

The present work is an *in silico* attempt to propose lead molecules as potential inhibitors of coronavirus 3CL^pro^ enzyme. Our study unravels new chemical entities from a repertoire of phytochemicals and FDA approved drugs that could be repurposed for treatment of coronavirus infection in humans. The leads suggested from this study could offer new candidate molecules in the drug discovery pipeline for the treatment and management of the disease. The current work is limited by small datasets and therefore, it would be worth exploring new chemical databases with big ligand sets for virtual screening procedure for identification of novel inhibitors against the target enzyme. A combined molecular docking and molecular dynamics simulation approach could be envisaged which would further provide useful mechanistic insights into the binding modes of inhibitions at the atomic level. Further research work is necessary to establish the inhibitory activity of the identified FDA approved lead molecules against the coronavirus 3CL^pro^ enzyme through *in vitro* and *in vivo* experiments.
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